Inhalation Sciences receives order worth approx. 3 MSEK from leading big pharma company
(Stockholm December 11, 2019) Inhalation Sciences (ISAB) has received an order for a PreciseInhale aerosol R&D system with an intratracheal exposure module, a Nose-Only exposure module and ISAB’s leading in vitro simulation module DissolvIt. The total purchase order is worth 317,000 USD or 2992k SEK (current currency conversion rate).
The order comes from a leading pharmaceutical company, and is their first order placed with Inhalation Sciences. The buyer has an extensive pipeline and this PreciseInhale-system is planned to be used at one of the company’s US-based affiliates.
With this order, Inhalation Sciences affirms its position in the marketplace, with this instrument being the second PreciseInhale system for the US.
“This confirms both the growing strength of our sales” says CEO Manoush Masarrat, “and how many more companies are recognizing that the data PreciseInhale delivers really can help them keep their lead in inhalation.”
“We recently reported that our sales up to and including October 2019 had increased 209% compared to the same period in 2018. New orders of this magnitude from reputable industrial partners are a key part of supporting this kind of growth.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the agency of the contact person above, for publication on December 11th 2019.
Tags: